当前位置: 首页 >> 检索结果
1141. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
作者: M C Dubinsky.;S Lamothe.;H Y Yang.;S R Targan.;D Sinnett.;Y Théorêt.;E G Seidman.
来源: Gastroenterology. 2000年118卷4期705-13页
The effects of 6-mercaptopurine (6-MP) are mediated via its intracellular conversion to 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP) nucleotide metabolites, the latter genetically controlled by thiopurine methyltransferase (TPMT). We sought to determine optimal therapeutic 6-MP metabolite levels and their correlation with medication-induced toxicity and TPMT genotype.
1142. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
作者: E A Lew.;J R Pisegna.;J A Starr.;E F Soffer.;C Forsmark.;I M Modlin.;J H Walsh.;M Beg.;W Bochenek.;D C Metz.
来源: Gastroenterology. 2000年118卷4期696-704页
Parenteral control of gastric acid hypersecretion in conditions such as Zollinger-Ellison syndrome (ZES) or idiopathic gastric acid hypersecretion is necessary perioperatively or when oral medications cannot be taken for other reasons (e.g., during chemotherapy, acute upper gastrointestinal bleeding, or in intensive care unit settings).
1143. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus.
作者: C Ell.;A May.;L Gossner.;O Pech.;E Günter.;G Mayer.;R Henrich.;M Vieth.;H Müller.;G Seitz.;M Stolte.
来源: Gastroenterology. 2000年118卷4期670-7页
In view of the mortality and morbidity rates of esophagectomy and the relatively large group of inoperable patients, local therapeutic techniques are required for high-grade dysplasia and early Barrett's cancer.
1144. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders.
Interleukin (IL)-10 is a cytokine that down-regulates the proinflammatory response and has a modulatory effect on hepatic fibrogenesis. The aim of this study was to determine the effect of IL-10 on hepatic injury in patients with chronic hepatitis C.
1147. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
作者: C M Prather.;M Camilleri.;A R Zinsmeister.;S McKinzie.;G Thomforde.
来源: Gastroenterology. 2000年118卷3期463-8页
This study evaluated the effects of a partial 5-hydroxytryptamine (5-HT)(4) agonist, tegaserod, on gastric small bowel and colonic transit in constipation-predominant irritable bowel syndrome (IBS).
1148. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
作者: M E Cramp.;S Rossol.;S Chokshi.;P Carucci.;R Williams.;N V Naoumov.
来源: Gastroenterology. 2000年118卷2期346-55页
The role of virus-specific T-helper lymphocyte reactivity in determining the therapeutic response in chronic hepatitis C virus (HCV) infection is not fully understood.
1149. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
作者: H Lochs.;M Mayer.;W E Fleig.;P B Mortensen.;P Bauer.;D Genser.;W Petritsch.;M Raithel.;R Hoffmann.;V Gross.;M Plauth.;M Staun.;L B Nesje.
来源: Gastroenterology. 2000年118卷2期264-73页
This study investigated if long-term treatment with high-dose mesalamine reduces the risk of clinical relapse of Crohn's disease after surgical resection.
1150. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia.
作者: M Bortolotti.;C Mari.;C Lopilato.;G Porrazzo.;M Miglioli.
来源: Gastroenterology. 2000年118卷2期253-7页
Sildenafil shows an intense and prolonged inhibitory effect on the smooth muscle cells of the human corpus cavernosum by blocking phosphodiesterase type 5 that destroys nitric oxide-stimulated cyclic guanosine monophosphate. We investigated if sildenafil possesses a similar effect on the esophageal musculature of patients with achalasia, where there is an impairment of nitric oxide production similar to that of functional impotence.
1151. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects.
Transient lower esophageal sphincter (LES) relaxations are the major mechanism of gastroesophageal reflux in normal subjects and in most patients with reflux disease. gamma-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter within the central nervous system which is present in regions of the brainstem that are believed to mediate transient LES relaxations. The aim of this study was to investigate the effect of a GABA(B) agonist baclofen on postprandial gastroesophageal reflux and transient LES relaxations.
1152. Unsedated small-caliber esophagogastroduodenoscopy (EGD) versus conventional EGD: a comparative study.
Significant portions of the cost and complications of esophagogastroduodenoscopy (EGD) are related to sedation. This study aimed to assess the feasibility, acceptability, and accuracy of unsedated small-caliber transoral EGD (sc-EGD).
1153. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.
作者: E A Vasiliauskas.;L Y Kam.;M T Abreu-Martin.;P V Hassard.;K A Papadakis.;H Yang.;J B Zeldis.;S R Targan.
来源: Gastroenterology. 1999年117卷6期1278-87页
Thalidomide decreases production of tumor necrosis factor alpha, a proinflammatory cytokine associated with Crohn's disease (CD). In this study the safety, tolerance, and efficacy of low-dose thalidomide were evaluated for treatment of moderate-to-severe, steroid-dependent CD.
1154. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.
作者: E D Ehrenpreis.;S V Kane.;L B Cohen.;R D Cohen.;S B Hanauer.
来源: Gastroenterology. 1999年117卷6期1271-7页
Inhibition of tumor necrosis factor is a proposed mechanism for the anti-inflammatory properties of thalidomide. We performed an open-label trial of thalidomide in refractory Crohn's disease.
1156. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis.
作者: M M Kaplan.;C Schmid.;D Provenzale.;A Sharma.;G Dickstein.;A McKusick.
来源: Gastroenterology. 1999年117卷5期1173-80页
The aim of this study was to determine if colchicine or methotrexate improves blood test results, symptoms, and/or liver histology in patients with primary biliary cirrhosis.
1157. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.
作者: M L Shiffman.;C M Hofmann.;M J Contos.;V A Luketic.;A J Sanyal.;R K Sterling.;A Ferreira-Gonzalez.;A S Mills.;C Garret.
来源: Gastroenterology. 1999年117卷5期1164-72页
: At least half of patients with chronic hepatitis C virus (HCV) fail to respond to interferon or interferon/ribavirin therapy. Histological improvement is observed in some nonresponders. We conducted a randomized, controlled trial to determine if maintenance interferon therapy could prevent histological progression in this subset of nonresponders.
1158. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.
作者: M Leuschner.;K P Maier.;J Schlichting.;S Strahl.;G Herrmann.;H H Dahm.;H Ackermann.;J Happ.;U Leuschner.
来源: Gastroenterology. 1999年117卷4期918-25页
Ursodeoxycholic acid (UDCA) is used for treatment of primary biliary cirrhosis. Previous studies showed that, compared with UDCA monotherapy, bile salts plus prednisolone had no further effect on laboratory data but improved liver histology. Thirty percent of these patients had prednisolone-related side effects. Budesonide is a glucocorticoid with a high receptor affinity and a high first-pass metabolism. In this study we investigated whether budesonide and UDCA are superior to UDCA monotherapy.
1159. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.
作者: A Attar.;B Flourié.;J C Rambaud.;C Franchisseur.;P Ruszniewski.;Y Bouhnik.
来源: Gastroenterology. 1999年117卷4期794-7页
No controlled trial has examined the clinical efficacy of antibiotics in small bowel bacterial overgrowth.
1160. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
作者: L Laine.;S Harper.;T Simon.;R Bath.;J Johanson.;H Schwartz.;S Stern.;H Quan.;J Bolognese.
来源: Gastroenterology. 1999年117卷4期776-83页
Prostaglandin production in the normal gastrointestinal tract, believed to be critical for mucosal integrity, is mediated by cyclooxygenase (COX)-1, whereas prostaglandin production at inflammatory sites seems to occur via induction of COX-2. We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor.
|